{"id":177358,"date":"2026-01-23T07:36:22","date_gmt":"2026-01-23T12:36:22","guid":{"rendered":"https:\/\/alphastreet.com\/india\/?p=177358"},"modified":"2026-01-23T07:36:25","modified_gmt":"2026-01-23T12:36:25","slug":"laurus-labs-q3-fy26-earnings-results","status":"publish","type":"post","link":"https:\/\/alphastreet.com\/india\/laurus-labs-q3-fy26-earnings-results\/","title":{"rendered":"Laurus Labs Q3 FY26 Earnings Results"},"content":{"rendered":"\n<p>Founded in 2005, Laurus Labs is a research-driven pharmaceutical and biotechnology company having a global leadership position in select Active Pharmaceutical Ingredients (APIs) including anti-retroviral, oncology drugs (incl High Potent APIs), Cardiovascular, and Gastro therapeutics. They also offer integrated CMO and CDMO services to Global Innovators from Clinical phase drug development to commercial manufacturing. Laurus employs 6500+ people, including around 1050+ scientists at more than 11 facilities approved by global agencies USFDA, WHO-Geneva, Japan-PDMA, UK-MHRA, EMA, TGA etc.<\/p>\n\n\n\n<div style=\"height:34px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Q3 FY26 Earnings Results<\/strong><\/h2>\n\n\n\n<p>Laurus Labs delivered stellar Q3 FY26 results with 26% revenue growth and 174% net profit surge, driven by robust generics demand and operational leverage.<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Revenue from Operations<\/strong>: \u20b91,778 crore, up 26% YoY from \u20b91,415 crore; up 7.5% QoQ from \u20b91,654 crore.<\/li>\n\n\n\n<li><strong>EBITDA<\/strong>: \u20b9485 crore, up 70% YoY from \u20b9285 crore; EBITDA margin 27.3%.<\/li>\n\n\n\n<li><strong>Profit Before Tax (PBT)<\/strong>: \u20b9353 crore (implied), up significantly YoY.\u200b<\/li>\n\n\n\n<li><strong>Profit After Tax (PAT)<\/strong>: \u20b9252 crore, up 174% YoY from \u20b992 crore; up 30% QoQ from \u20b9194 crore.<\/li>\n\n\n\n<li><strong>EPS<\/strong>: \u20b94.67, up significantly YoY.\u200b<\/li>\n\n\n\n<li><strong>Segments<\/strong>:\n<ul class=\"wp-block-list\">\n<li>Generics: \u20b91,327 crore (up 37% YoY).\u200b<\/li>\n\n\n\n<li>CDMO Small Molecules: \u20b9408 crore (up 2% YoY).\u200b<\/li>\n<\/ul>\n<\/li>\n\n\n\n<li><strong>9M FY26<\/strong>: Revenue \u20b95,001 crore (up 30% YoY); EBITDA \u20b91,303 crore (up 104% YoY); PAT \u20b9608 crore (up 5x YoY); EBITDA margin 26.1%.<\/li>\n<\/ul>\n\n\n\n<div style=\"height:33px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Management Commentary &amp; Strategic Decisions \u2013 Q3 FY26<\/strong><\/h2>\n\n\n\n<p>&#8220;We delivered another <a href=\"https:\/\/www.bseindia.com\/xml-data\/corpfiling\/AttachLive\/1029229c-0a32-4970-b587-97a680bf2bc6.pdf\" target=\"_blank\" rel=\"noopener\">quarter of strong operational and financial performance<\/a>, based on strong Generic business and continued demand upside in CDMO small molecule offerings.&#8221; &#8211; V V Ravi Kumar, ED &amp; CFO.<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Gross Margin<\/strong>: 60.1% (up 430 bps YoY).\u200b<\/li>\n\n\n\n<li><strong>Net Debt Leverage<\/strong>: 1.2x EBITDA (improved).\u200b<\/li>\n\n\n\n<li><strong>Outlook<\/strong>: Continued investments in high-value opportunities to drive growth.<\/li>\n<\/ul>\n\n\n\n<figure class=\"wp-block-image size-large\"><img loading=\"lazy\" decoding=\"async\" width=\"839\" height=\"1024\" src=\"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/image-37-839x1024.png\" alt=\"\" class=\"wp-image-177360\" srcset=\"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/image-37-839x1024.png 839w, https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/image-37-246x300.png 246w, https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/image-37-768x937.png 768w, https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/image-37-1259x1536.png 1259w, https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/image-37.png 1489w\" sizes=\"auto, (max-width: 839px) 100vw, 839px\" \/><\/figure>\n\n\n\n<div style=\"height:36px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Q2 FY26 Earnings Results<\/strong><\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Revenue from Operations<\/strong>: \u20b91,653 crore, up 35% YoY from \u20b91,224 crore; up 35% QoQ.<\/li>\n\n\n\n<li><strong>EBITDA<\/strong>: \u20b9429 crore, up 136% YoY from \u20b9182 crore; margin 26% (up 1,110 bps YoY).<\/li>\n\n\n\n<li><strong>Profit After Tax (PAT)<\/strong>: \u20b9195 crore (up 875% YoY); EPS \u20b93.61.<\/li>\n\n\n\n<li><strong>H1 FY26<\/strong>: Revenue \u20b93,223 crore (up 35% YoY).\u200b<\/li>\n<\/ul>\n\n\n\n<div style=\"height:36px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Management Commentary &amp; Strategic Directions \u2013 Q2 FY26<\/strong><\/h2>\n\n\n\n<p>Strong growth from CDMO (up 53% YoY to \u20b9518 crore) and generics (up 28%); interim dividend \u20b90.80\/share declared.<\/p>\n\n\n\n<p>To view the company\u2019s previous earnings and latest concall transcripts,&nbsp;<a href=\"https:\/\/alphastreet.com\/india\/\">click here<\/a>&nbsp; to visit the Alphastreet India news channel.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Founded in 2005, Laurus Labs is a research-driven pharmaceutical and biotechnology company having a global leadership position in select Active Pharmaceutical Ingredients (APIs) including anti-retroviral, oncology drugs (incl High Potent APIs), Cardiovascular, and Gastro therapeutics. They also offer integrated CMO and CDMO services to Global Innovators from Clinical phase drug development to commercial manufacturing. Laurus [&hellip;]<\/p>\n","protected":false},"author":1863,"featured_media":177360,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[105,5747],"tags":[1115],"class_list":["post-177358","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-infographics","category-healthcare-stocks","tag-pharmaceuticals"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/image-37.png","jetpack_likes_enabled":false,"jetpack-related-posts":[{"id":171767,"url":"https:\/\/alphastreet.com\/india\/laurus-labs-q2-fy26-earnings-results\/","url_meta":{"origin":177358,"position":0},"title":"Laurus Labs Q2 FY26 Earnings Results","author":"Chirag Gupta","date":"October 23, 2025","format":false,"excerpt":"Founded in 2005, Laurus Labs is a research-driven pharmaceutical and biotechnology company having a global leadership position in select Active Pharmaceutical Ingredients (APIs) including anti-retroviral, oncology drugs (incl High Potent APIs), Cardiovascular, and Gastro therapeutics. They also offer integrated CMO and CDMO services to Global Innovators from Clinical phase drug\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"Laurus Labs Q2 FY26 Earnings Results","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/10\/Laurus-Labs-Q2-FY26-Earnings.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/10\/Laurus-Labs-Q2-FY26-Earnings.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/10\/Laurus-Labs-Q2-FY26-Earnings.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/10\/Laurus-Labs-Q2-FY26-Earnings.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/10\/Laurus-Labs-Q2-FY26-Earnings.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/10\/Laurus-Labs-Q2-FY26-Earnings.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":169505,"url":"https:\/\/alphastreet.com\/india\/laurus-labs-ltd-q1-fy26-earnings-results-a-whopping-1146-rise-in-profits\/","url_meta":{"origin":177358,"position":1},"title":"Laurus Labs Ltd Q1 FY26 Earnings Results &#8211; A whopping 1146% rise in Profits","author":"Chirag Gupta","date":"July 29, 2025","format":false,"excerpt":"Founded in 2005, Laurus Labs is a research-driven pharmaceutical and biotechnology company having a global leadership position in select Active Pharmaceutical Ingredients (APIs) including anti-retroviral, oncology drugs (incl High Potent APIs), Cardiovascular, and Gastro therapeutics. They also offer integrated CMO and CDMO services to Global Innovators from Clinical phase drug\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/5-2.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/5-2.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/5-2.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/5-2.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/5-2.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/5-2.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":166795,"url":"https:\/\/alphastreet.com\/india\/laurus-labs-ltd-q3fy25-304-rise-in-profits\/","url_meta":{"origin":177358,"position":2},"title":"Laurus Labs Ltd Q3FY25; 304% rise in Profits","author":"Chirag Gupta","date":"February 11, 2025","format":false,"excerpt":"Founded in 2005, Laurus Labs is a research-driven pharmaceutical and biotechnology company having a global leadership position in select Active Pharmaceutical Ingredients (APIs) including anti-retroviral, oncology drugs (incl High Potent APIs), Cardiovascular, and Gastro therapeutics. They also offer integrated CMO and CDMO services to Global Innovators from Clinical phase drug\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/02\/2-6.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/02\/2-6.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/02\/2-6.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/02\/2-6.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/02\/2-6.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/02\/2-6.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":168672,"url":"https:\/\/alphastreet.com\/india\/laurus-labs-ltd-q4fy25-211-rise-in-profits\/","url_meta":{"origin":177358,"position":3},"title":"Laurus Labs Ltd Q4FY25; 211% rise in Profits","author":"Chirag Gupta","date":"June 5, 2025","format":false,"excerpt":"Founded in 2005, Laurus Labs is a research-driven pharmaceutical and biotechnology company having a global leadership position in select Active Pharmaceutical Ingredients (APIs) including anti-retroviral, oncology drugs (incl High Potent APIs), Cardiovascular, and Gastro therapeutics. They also offer integrated CMO and CDMO services to Global Innovators from Clinical phase drug\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/06\/3-2.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/06\/3-2.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/06\/3-2.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/06\/3-2.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/06\/3-2.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/06\/3-2.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":163407,"url":"https:\/\/alphastreet.com\/india\/laurus-labs-ltd-q1fy25-52-fall-in-profits\/","url_meta":{"origin":177358,"position":4},"title":"Laurus Labs Ltd Q1FY25; 52% fall in Profits","author":"Chirag Gupta","date":"July 31, 2024","format":false,"excerpt":"Founded in 2005, Laurus Labs is a research-driven pharmaceutical and biotechnology company having a global leadership position in select Active Pharmaceutical Ingredients (APIs) including anti-retroviral, oncology drugs (incl High Potent APIs), Cardiovascular, and Gastro therapeutics. They also offer integrated CMO and CDMO services to Global Innovators from Clinical phase drug\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/07\/image-204.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/07\/image-204.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/07\/image-204.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/07\/image-204.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/07\/image-204.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/07\/image-204.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":160534,"url":"https:\/\/alphastreet.com\/india\/laurus-labs-ltd-q4fy24-29-fall-in-profits\/","url_meta":{"origin":177358,"position":5},"title":"Laurus Labs Ltd Q4FY24; 29% fall in Profits","author":"Chirag Gupta","date":"April 25, 2024","format":false,"excerpt":"Founded in 2005, Laurus Labs is a research-driven pharmaceutical and biotechnology company having a global leadership position in select Active Pharmaceutical Ingredients (APIs) including anti-retroviral, oncology drugs (incl High Potent APIs), Cardiovascular, and Gastro therapeutics. They also offer integrated CMO and CDMO services to Global Innovators from Clinical phase drug\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/04\/image-42.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/04\/image-42.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/04\/image-42.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/04\/image-42.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/04\/image-42.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/04\/image-42.png?resize=1400%2C800&ssl=1 4x"},"classes":[]}],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/177358","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/users\/1863"}],"replies":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/comments?post=177358"}],"version-history":[{"count":1,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/177358\/revisions"}],"predecessor-version":[{"id":177363,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/177358\/revisions\/177363"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media\/177360"}],"wp:attachment":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media?parent=177358"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/categories?post=177358"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/tags?post=177358"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}